Contact PI/Project LeaderGERSTENFELD, LOUIS CHARLES
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
Distraction osteogenesis (DO) is a widely used orthopedic treatment for the correction of limb length discrepancies, congenital deformities, non-unions, and the regeneration of large amounts of bone that have been lost due to trauma. It is one of the most dramatic applications of mechanical stimulation as a means of inducing regeneration of up to 20% of the length of a long bone. While DO procedures are used clinically and the surgical techniques have been refined, the basic mechanisms by which this procedure promotes new bone formation are not
well understood. One of the primary descriptive features of distraction osteogenesis is that it induces new bone formation through an intramembranous processes devoid of extensive amounts of cartilage. However, the most intriguing observation is that the regeneration of abundant amounts of bone is accompanied by robust vascularity of the repair tissue throughout the regenerative process. The hypothesis of this proposal is that bone regeneration during distraction osteogenesis is driven by an angiogenic process. A component of this
hypothesis is that the angiogenic events that accompany the regenerative process in distraction osteogenesis are the primary regulatory mechanisms that direct bone formation in the absence of chondrogenesis. In order to test this hypothesis and examine genetic models that will define the molecular mechanisms regulating bone formation, we have developed a murine model of DO. Initial studies will define the temporal and spatial expression of the angiogenic and bone morphogenetic signals that drive new bone formation during distraction osteogenesis and
compare the expression of these signals to those that drive the endochondral repair processes that occur during fracture healing (these will be elucidated as part of Project 4). This will be followed with experiments in which we specifically block vascular endothelial growth factor (VEGF)-mediated angiogenesis using selective blocking antibodies to two different receptors of VEGF (Flk- 1 and Flt- 1), and functionally test the degree to which VEGF signals are mediators of both angiogenesis and/or new bone formation during distraction angiogenesis. We will
test, in both in vivo and in vitro experiments, the relationship of BMP-2 stimulated differentiation to the expression of VEGF(s) and the inverse effects of VEGF on the expression of BMP(s). We will then determine how selective gain or loss of BMP activity during DO affects angiogenesis and how these alterations affect the formation of bone in this system.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
Project End Date
Budget Start Date
01-June-2006
Budget End Date
31-May-2007
Project Funding Information for 2006
Total Funding
$215,657
Direct Costs
$133,534
Indirect Costs
$82,123
Year
Funding IC
FY Total Cost by IC
2006
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$215,657
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AR049920-03 0001
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AR049920-03 0001
Patents
No Patents information available for 5P01AR049920-03 0001
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AR049920-03 0001
Clinical Studies
No Clinical Studies information available for 5P01AR049920-03 0001
News and More
Related News Releases
No news release information available for 5P01AR049920-03 0001
History
No Historical information available for 5P01AR049920-03 0001
Similar Projects
No Similar Projects information available for 5P01AR049920-03 0001